KPTI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Karyopharm Therapeutics Inc (KPTI) is not a strong buy for a beginner, long-term investor with $50,000-$100,000 available for investment. While the company has shown some positive financial trends and an Overweight analyst rating, the lack of significant positive catalysts, insider selling, and weak technical indicators suggest that it is better to hold off on investing in this stock at the moment.
The MACD is negative and expanding, indicating bearish momentum. RSI is neutral at 37.623, and the stock is trading near its support level (S1: 8.851). Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), but the overall technical indicators do not provide a strong buy signal.
Analyst Overweight rating with a 70% probability of success for the Phase 3 SENTRY trial in myelofibrosis.
Revenue increased by 11.58% YoY in Q4 2025.
Insiders are selling heavily, with a 599.43% increase in selling activity over the last month.
No recent news or event-driven catalysts.
Net income remains negative despite improvement, and EPS is still in the negative range.
In Q4 2025, revenue increased by 11.58% YoY to $34,079,000. Net income improved by 232.03% YoY but remains negative at -$102,198,000. EPS increased by 54.77% YoY to -$5.68. Gross margin slightly improved to 95.65%.
Cantor Fitzgerald initiated coverage with an Overweight rating, citing a 70% probability of success for the Phase 3 SENTRY trial. A successful trial could significantly reposition the company in the market.
